Date |
Title |
|
IMMUNOMEDICS ANNOUNCES COMBINATION THERAPY OF MILATUZUMAB AND RITUXIMAB IS ACTIVE IN MANTLE CELL LYMPHOMA MODELS |
|
IMMUNOMEDICS REPORTS INITIAL RESULTS FROM PHASE I/II STUDY OF VELTUZUMAB IN IMMUNE THROMBOCYTOPENIC PURPURA
|
|
IMMUNOMEDICS REPORTS PRELIMINARY RESULTS OF MILATUZUMAB IN MULTIPLE MYELOMA STUDY
-- Results From First Trial of Humanized Anti-CD74 Antibody Presented at the 50th Annual Meeting of ASH --
|
|
IMMUNOMEDICS TO PRESENT AT 50th ASH ANNUAL MEETING |
|
IMMUNOMEDICS TO PRESENT AT LAZARD CAPITAL MARKETS |
|
IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2009 RESULTS |
|
IMMUNOMEDICS ANNOUNCES U.S. PATENTS AWARDED FOR CD20 ANTIBODY, VELTUZUMAB, AND REAGENTS USED IN PRETARGETED IMAGING AND THERAPIES |
|
IMMUNOMEDICS HIGHLIGHTS PROGRESS WITH CLINICAL PROGRAMS AT R&D DAY |
|
IMMUNOMEDICS TO HOST R&D DAY |
|
IMMUNOMEDICS ANNOUNCES FISCAL 2008 RESULTS |
|
RESULTS WITH EPRATUZUMAB IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA PUBLISHED IN JOURNAL OF CLINICAL ONCOLOGY |
|
IMMUNOMEDICS ANNOUNCES WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH NYCOMED FOR VELTUZUMAB FOR NON-CANCER INDICATIONS |
|
IMMUNOMEDICS ANNOUNCES FRACTIONATED PRETARGETED RADIOIMMUNOTHERAPY IMPROVES PANCREATIC CANCER THERAPY IN ANIMAL MODEL |
|
IMMUNOMEDICS DEVELOPS NOVEL RADIOTRACER FOR IMPROVED PET IMAGING OF CANCER |
|
IMMUNOMEDICS’ PRETARGETING METHOD MAY IMPROVE RADIOIMMUNOIMAGING OF CANCER |
|
IMMUNOMEDICS TO PRESENT AT THE SOCIETY OF NUCLEAR MEDICINE 55th ANNUAL MEETING |
|
IMMUNOMEDICS REPORTS CLINICAL RESULTS IN LYMPHOMA AND METASTATIC COLORECTAL CANCER WITH RADIOIMMUNOTHERAPY (RAIT) |
|
NORTH CENTRAL CANCER TREATMENT GROUP PRESENTS PHASE II STUDY RESULTS THAT EPRATUZUMAB IN COMBINATION WITH RITUXIMAB AND CHEMOTHERAPY IS ACTIVE, SAFE AND TOLERABLE IN AGGRESSIVE LYMPHOMA |
|
IMMUNOMEDICS REPORTS HIGH ANTI-LYMPHOMA POTENCY WITH VELTUZUMAB |
|
IMMUNOMEDICS’ PRODUCT CANDIDATES BEING PRESENTED AT 2008 ASCO ANNUAL MEETING |
|
IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2008 RESULTS |
|
IMMUNOMEDICS CREATES NOVEL CYTOKINE IMMUNOCONJUGATES USING DOCK-AND-LOCK |
|
IMMUNOMEDICS' MILATUZUMAB MAY ENHANCE EFFICACIES OF THERAPEUTICS FOR MULTIPLE MYELOMA IN PRECLINICAL STUDIES' |
|
IMMUNOMEDICS REPORTS VELTUZUMAB ENHANCES RADIO IMMUNOTHERAPY WITH EPRATUZUMAB IN LYMPHOMA MODEL |
|
IMMUNOMEDICS PRETARGETING METHOD MAY IMPROVE RADIO IMMUNOTHERAPY OF CANCER |
|
IMMUNOMEDICS PRODUCT CANDIDATES BEING PRESENTED AT 2008 AMERICAN ASSOCIATION FOR CANCER
RESEARCH ANNUAL MEETING |
|
IMMUNOMEDICS ANNOUNCES RESULTS IN LYMPHOMA THERAPY WITH VELTUZUMAB ADMINISTERED SUBCUTANEOUSLY |
|
IMMUNOMEDICS AWARDED U.S. PATENT FOR USE OF ANTI-CD74 IMMUNOCONJUGATES TO ENHANCE EFFICACY OF
CANCER AND INFECTIOUS DISEASE VACCINES |
|
IMMUNOMEDICS DEVELOPS NEW IMMUNOCONJUGATES FOR TARGETED CHEMOTHERAPY OF PANCREATIC AND OTHER CANCERS |
|
IMMUNOMEDICS' MILATUZUMAB RECEIVES FDA ORPHAN DRUG DESIGNATION FOR THERAPY OF MULTIPLE MYELOMA |
|
IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2008 RESULTS |
|
IMMUNOMEDICS ANNOUNCES FIRST PATIENT DOSING OF VELTUZUMAB, RESULTING IN A COMPLETE RESPONSE, IN IMMUNE THROMBOCYTOPENIC PURPUR |
|
IMMUNOMEDICS AWARDED U.S. PATENT FOR INTERNALIZING ANTI-CD74 ANTIBODIES AND METHODS OF USE |
